Evidence mapPaperPMID 40173198Full record

ArticlePLoS genetics2025

Identification of modifier gene variants overrepresented in familial hypomagnesemia with hypercalciuria and nephrocalcinosis patients with a more aggressive renal phenotype.

Monica Vall-Palomar, Julieta Torchia, Jordi Morata, Monica Durán, Raul Tonda, Mireia Ferrer, Alex Sánchez, Gerard Cantero-Recasens, Gema Ariceta, Anna Meseguer and 1 more

Abstract read
In one paragraph

Article in PLoS genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Monica Vall-PalomarRenal Physiopathology Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
Julieta TorchiaRenal Physiopathology Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
Jordi MorataCNAG, Centro Nacional de Análisis Genómico, Barcelona, Spain.
Monica DuránRenal Physiopathology Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
Raul TondaCNAG, Centro Nacional de Análisis Genómico, Barcelona, Spain.
Mireia FerrerStatistics and Bioinformatic Unit (UEB), Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
Alex SánchezStatistics and Bioinformatic Unit (UEB), Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
Gerard Cantero-RecasensRenal Physiopathology Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.ORCID https://orcid.org/0000-0001-6452-782X
Gema AricetaRenal Physiopathology Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
Anna MeseguerRenal Physiopathology Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.ORCID https://orcid.org/0000-0003-3833-2249
Cristina MartinezRenal Physiopathology Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.ORCID https://orcid.org/0000-0002-9368-1356

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) is an ultra-rare autosomal recessive renal tubular disease with an incidence of <1/1.000.000 individuals, caused by loss-of-function mutations in CLDN16 and CLDN19. Our study includes a unique cohort representing all known FHHNC patients in Spain, with 90% harbouring mutations in CLDN19. Of these, 70% carry the p.G20D mutation in homozygosis. Despite this high genetic homogeneity, our FHHNC cohort display a high phenotypic variability, even among siblings harbouring identical mutations. Patients were stratified at the extremes of the renal phenotype according to their estimated glomerular filtration rate annual decline and subjected to whole exome sequencing (WES) aiming to find candidate phenotype-modifier genes. Initial statistical analysis by SKAT-O identified numerous variants, which were then filtered based on P-value <0.01 and kidney expression. A thorough prioritization strategy was then applied by an exhaustive disease knowledge-driven exploitation of data from public databases (Human Protein Atlas, GWAS catalog, GTEx) to further refine candidate genes. Odds ratios were also calculated to identify potential risk variants. This analysis pipeline suggested several gene variants associated with a higher risk of developing a more aggressive renal phenotype. While these findings hint at the existence of genetic modifiers in FHHNC, further research is needed to confirm their role and potential clinical significance. Clinical decisions should not be based on these preliminary findings, and additional cohorts should be studied to validate and expand upon our results. This exploratory study provides a foundation for future investigations into the genetic factors influencing FHHNC progression and may contribute to our understanding of the disease's variable expressivity potentially enabling the implementation of more tailored therapeutic strategies.

Indexed as

ClaudinsGenes, ModifierHypercalciuriaNephrocalcinosisRenal Tubular Transport, Inborn ErrorsAdolescentAdultChildChild, PreschoolExome SequencingFemaleHumansKidneyMaleMutationPhenotypeclaudin 16ClaudinsCLDN19 protein, human

Identifiers

PMID40173198
PMCPMC12005529

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.